As the combination therapy of TRAIL and R-roscovitine was effective in inducing cell death in both the monolayer and 3D neurospheres of a formerly treatment-resistant GBM cell line, yet R-roscovitine was not capable of altering the expression of the TRAIL receptors DR4 and DR5 (Supplemental Fig 1), we focused our investigation on the downstream cell death signalling pathways elicited by this drug combination. The gene discussed is TNFRSF10A; the disease is glioblastoma.